Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial.

Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, Shear CL, Duggan WT, Vicari RM, Grobbee DE, Kastelein JJ; RADIANCE 2 Investigators.

Lancet. 2007 Jul 14;370(9582):153-60.

PMID:
17630038
2.

Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis.

Li C, Zhang W, Zhou F, Chen C, Zhou L, Li Y, Liu L, Pei F, Luo H, Hu Z, Cai J, Zeng C.

PLoS One. 2013 Oct 28;8(10):e77049. doi: 10.1371/journal.pone.0077049. eCollection 2013. Review.

3.

Meta-analysis of the comparative efficacy and safety of pitavastatin and atorvastatin in patients with dyslipidaemia.

Poolsup N, Suksomboon N, Wongyaowarat K, Rungkanchananon B, Niyomrat P, Kongsuwan S.

J Clin Pharm Ther. 2012 Apr;37(2):166-72. doi: 10.1111/j.1365-2710.2011.01274.x. Epub 2011 May 18. Review.

PMID:
21585411
4.
5.

Pitavastatin: novel effects on lipid parameters.

Chapman MJ.

Atheroscler Suppl. 2011 Nov;12(3):277-84. doi: 10.1016/S1567-5688(11)70887-X. Review.

PMID:
22152282
6.
7.

[HDL level or HDL function as the primary target in preventive cardiology].

Schaefer JR.

Herz. 2012 Feb;37(1):51-5. doi: 10.1007/s00059-011-3563-z. Review. German.

PMID:
22258137
8.

The role of CETP inhibition in dyslipidemia.

El Harchaoui K, van der Steeg WA, Stroes ES, Kastelein JJ.

Curr Atheroscler Rep. 2007 Aug;9(2):125-33. Review.

PMID:
17877921
9.

The hypertension peril: lessons from CETP inhibitors.

Hermann M, Ruschitzka FT.

Curr Hypertens Rep. 2009 Feb;11(1):76-80. Review.

PMID:
19146805
11.

Will torcetrapib be the next big thing in coronary heart disease risk reduction?

McKenney JM, Hoekstra JA.

Curr Atheroscler Rep. 2007 Jan;9(1):48-56. Review.

PMID:
17169247

Supplemental Content

Support Center